Written in Blood

Written in Blood

Research from recent issues of Blood

WIB_icon

Risk of Subsequent Malignant Neoplasms Is Low in Children With Hodgkin Lymphoma

A study published in Blood suggests that children and adolescents with intermediate-risk Hodgkin lymphoma have a relatively low cumulative risk of developing subsequent malignant...
WIB_icon

Adults With Hematologic Malignancies and COVID-19 Fare Worse Than Children

Adults with hematologic malignancies and COVID-19 infection have a substantially higher risk of death compared with children with hematologic malignancies and COVID-19, according to...
WIB_icon

Avelumab Shows Clinical Activity in Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma

Avelumab is clinically active in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (ENKTL), although researchers observed a lower-than-expected response rate, according to...
WIB_icon

Leukemia Antigen–Specific Donor-Derived T Cells Enhance Graft-Versus-Leukemia Effects in Post-Transplant AML/MDS

For patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) whose disease relapses following a hematopoietic cell transplantation (HCT), unselected donor lymphocytes typically...
WIB_icon

Researchers Develop a Validated Pediatric Disease Risk Index for AML and ALL

A pediatric disease risk index (DRI) reported in Blood was capable of stratifying children with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL)...
WIB_icon

CONTRALTO: Evaluating a Chemotherapy-Free Approach With Venetoclax in Relapsed/Refractory Follicular Lymphoma

A chemotherapy-free approach comprising venetoclax and rituximab (VEN+R) showed modest efficacy in the treatment of patients with relapsed/refractory follicular lymphoma and was outperformed by...
WIB_icon

Discontinuing Eculizumab is Safe and Feasible in Patients With Atypical Hemolytic Uremic Syndrome

Discontinuation of anti-C5 agent eculizumab is feasible and safe in patients with atypical hemolytic uremic syndrome (aHUS), particularly in the 40% to 60% of...
WIB_icon

Azacitidine and Romidepsin Combination Shows High Activity in Peripheral T-Cell Lymphoma

A combination regimen consisting of oral azacitidine and romidepsin was highly active in patients with peripheral T-cell lymphoma (PTCL), particularly in previously untreated patients...
WIB_icon

Machine Learning Detects Prognostic Associations Between Morphologic and Genetic Changes in MDS

A new artificial intelligence–based technique was able to establish correlations between genetic and morphologic biomarkers, revealing diagnostically and prognostically important relationships, according to results...
WIB_icon

Is Caplacizumab a Cost-Effective Strategy for Acquired TTP?

In February 2019, the FDA approved the anti–von Willebrand factor immunoglobulin fragment caplacizumab as the only agent specifically indicated for the treatment of adults...
Advertisement

Current Issue

March 2021 Volume 7 Issue 4

This issue examines blood services across the globe, the repercussions of increased patient access to medical information, and more.

Block title